Article Text

Download PDFPDF
EP843 Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: evaluation of side effects in a single institution cohort
  1. M Friedrich
  1. Academic Teaching Hospital | OB/Gyn, Helios Hospital, Krefeld, Germany


Introduction/Background Peritoneal carcinomatosis is a sign of advanced disease of ovarian cancer and cancer of the fallopian tubes. If it is possible to achieve a complete tumor free situation by cytoreductive surgery with remaining tumor rest less than 0.25 mm, HIPEC might may improve the prognosis.

Methodology Patients with ovarian cancer and peritoneal carcinomatosis underwent cytoreductive surgery. In patients with optimal tumor debulking HIPEC was performed. The peri- and postoperative course was observed. Adverse events were recorded after the Clavien-Dindo classification.

Results 43 patients were treated with cytoreductive surgery and HIPEC. In all 43 patients an optimal cytoreductive situation with remaining tumor rest less than 0.25 mm was achieved. HIPEC was performed with a cisplatin solution (50 mg/m2) at 41°C. The mean age of the patients was 57.4 years (range: 32–74 years) the median age was 56 years, the mean peritoneal cancer index (PCI) was 11.2 (range: 4–21), the median PCI was 13, the mean operation time was 348.6 minutes (range: 192–507 minutes). The mean time to postoperative systemic treatment with chemotherapy was 36.51 days (range 21–70), the median time was 29 days. There was no postoperative surgically associated death. No adverse events were recorded in 16 patients of the 43 patients, no grade III or IV adverse events were reported for 33. Grade III adverse events occured in 19; a total of 29 grade III adverse events were reported in these 19 patients. Grade IV adverse events occured in 3 patients. The only adverse event that resulted in a return to the operating room was a fistula of the distal small bowel caused by drainage.

Conclusion Since we have no marked additional adverse events caused by HIPEC we believe, HIPEC to be an additional additional important treatment option of peritoneal carcinomatosis in ovarian cancer.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.